Lenvima (lenvatinib) — Medica
Differentiated thyroid carcinoma
Initial criteria
- age ≥ 18 years
- Patient meets ONE of the following (i or ii):
- i. Patient has BOTH of the following: papillary or follicular thyroid carcinoma AND disease refractory to radioactive iodine therapy; OR
- ii. Patient has oncocytic (formerly Hürthle cell) carcinoma
Approval duration
1 year